Clinical trial
Investigation Of A New Medication (GW642444) In Asthmatic Patients
NCT00354874 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00354874 |
|---|---|
| Title | Investigation Of A New Medication (GW642444) In Asthmatic Patients |
| Official title | A Multi-centre, Randomised, Double-blind, Placebo Controlled, Dose Ascending, Four Way Crossover Study to Examine Efficacy (FEV1), Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Doses of GW642444 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | GW642444, Placebo, salmeterol 50mcg |
| Enrollment | 28 |
| Start date | Jan 1, 2005 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jul 20, 2006 |
| Last update posted | Sep 15, 2016 |
| Countries | Germany, Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: